CelLBxHealth plc (ANPCF) 株価予測

CelLBxHealth Plc is a holding company, which engages in the provision of its subsidiaries engages in providing products in cancer diagnostics and foetal health. The company is headquartered in Guildford, Surrey and currently employs 119 full-time employees. The company went IPO on 2004-03-17. The product portfolio comprises the Parsortix platform with associated consumables and assays. Its Parsortix platform harvests CTCs from blood and enables comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows - supporting research, drug development and clinical oncology. Its Parsortix PC1 system is the first FDA cleared medical device for the capture and harvest of intact CTCs from metastatic breast cancer (MBC) patient blood for subsequent, user-validated analysis.Its Parsortix PR1 System is a semi-automated platform for epitope-independent CTC isolation, used in research and clinical trials for multiple cancer types.